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Using computer simulation models 
to investigate the most promising 
microRNAs to improve muscle 
regeneration during ageing
Carole J. Proctor1 & Katarzyna Goljanek-Whysall2
MicroRNAs (miRNAs) regulate gene expression through interactions with target sites within mRNAs, 
leading to enhanced degradation of the mRNA or inhibition of translation. Skeletal muscle expresses 
many different miRNAs with important roles in adulthood myogenesis (regeneration) and myofibre 
hypertrophy and atrophy, processes associated with muscle ageing. However, the large number of 
miRNAs and their targets mean that a complex network of pathways exists, making it difficult to 
predict the effect of selected miRNAs on age-related muscle wasting. Computational modelling has the 
potential to aid this process as it is possible to combine models of individual miRNA:target interactions 
to form an integrated network. As yet, no models of these interactions in muscle exist. We created the 
first model of miRNA:target interactions in myogenesis based on experimental evidence of individual 
miRNAs which were next validated and used to make testable predictions. Our model confirms that 
miRNAs regulate key interactions during myogenesis and can act by promoting the switch between 
quiescent/proliferating/differentiating myoblasts and by maintaining the differentiation process. We 
propose that a threshold level of miR-1 acts in the initial switch to differentiation, with miR-181 keeping 
the switch on and miR-378 maintaining the differentiation and miR-143 inhibiting myogenesis.
Muscle homeostasis is perturbed in ageing leading to loss of muscle mass and function - sarcopenia. Muscle 
homeostasis depends on the balance between muscle hypertrophy and atrophy and successful muscle regen-
eration following injury. During ageing, muscle regeneration is defective and this is attributed, at least to some 
degree, to changes in satellite cell properties1,2. The mechanisms leading to this loss in homeostasis are not fully 
understood but it is hypothesised that changes in gene expression and dysregulation of cellular signalling path-
ways are key contributors. Recently, miRNAs have been shown to play important roles in muscle maintenance 
during adulthood and ageing3–5. Muscles express their own set of muscle-enriched miRNAs known as myomiRs: 
miR-1, -206, -208, -133, -486 and -4996. Satellite cells, adult muscle stem cells contributing to muscle regenera-
tion, express different sets of miRNAs during quiescence and activation1 suggesting the role of miRNAs in regu-
lating satellite cell homeostasis. Moreover, the expression profile of miRNAs in satellite cells and muscle is altered 
during exercise and ageing3,5,7,8. The formation of new muscle fibres and repair of injured myofibres (myogenesis) 
requires the differentiation of myogenic progenitors or satellite cells, respectively9 and several miRNAs have been 
shown to regulate myogenesis in adulthood, including miR-1, miR-206, miR-27, miR-378 and miR-1814,10–12.
We have shown that miR-1 and miR-206 down-regulate the expression of the transcription factor Pax3, which 
inhibits MyoD, a myogenic regulatory factor (MRF) that is essential for myogenesis to occur13. On the other 
hand, MyoD has been shown to upregulate the expression of many miRNAs, including miR-114. Pax3/Pax7 are 
expressed in embryonic myogenic progenitor cells and in quiescent satellite cells, whereas MyoD expression is 
low in the undifferentiated progenitors. Upon activation of satellite cells/myogenic progenitors, the expression of 
Pax3 is downregulated, whereas MyoD expression is upregulated following satellite cell activation. The downreg-
ulation of Pax3/Pax7 expression is partly mediated by miR-1 and miR-206, which ensure complete silencing of the 
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Pax genes to confer robustness to the timing of myogenesis in development13. In addition, miR-206 and miR-486 
have been shown to induce myoblast differentiation by downregulating Pax7 expression15, and miR-27 inhibits 
Pax3 expression in satellite cells16. It has also been shown that Pax3 protein is regulated by monoubiquitination 
and degradation by the proteasome17. On the other hand, MyoD expression has been shown to be inhibited by 
Musculin (Msc) (also known as MyoR), expressed during early stages of myogenesis and down-regulated at later 
stages. Therefore, the balance between these two, as well as other myogenic factors such as Myf-518, contributes to 
the regulation of early stages of myogenesis: commitment and differentiation. Moreover, the expression of miR-1 
and miR-133 has been shown to decrease during skeletal muscle hypertrophy and ageing7,19.
Another miRNA, miR-181, is strongly upregulated during myogenesis and positively regulates myogenic dif-
ferentiation through inhibiting Hox-A11, another antagonist of MyoD, expression12. miR-181 inhibits Hox-A11 
at the protein level, which suggests that it inhibits translation of Hox-A11 mRNA12. miR-181 has also been 
shown to inhibit Sirt-1 expression at the protein level, which leads to a decrease in myotube size20. This may 
be partly mediated by Sirt-1 inhibition of FoxO3, a transcription factor that upregulates the muscle-specific 
E3 ligase Mafbx which in turn leads to an increase in protein degradation and muscle atrophy. Interestingly, 
MyoD has been shown to be one of the targets of Mafbx21. Sirt-1 has also been shown to promote cell prolifera-
tion by decreasing the expression of the cyclin-dependent kinase inhibitor, p2122 and to block the induction of 
autophagy-related genes leading to a decrease in proteolysis23. Therefore, miR-181 may inhibit Sirt-1-induced 
hypertrophy. Moreover, upregulation of miR-181 may also lead to inhibition of myoblast proliferation. miR-181a 
has been shown to be down-regulated in mice and human skeletal tissue with age20, therefore it may contribute to 
dysregulation of myogenesis with age.
During myogenesis, MyoD activation leads to upregulation of the expression of several miRNAs, includ-
ing miR-378, an inhibitor of Msc11. miR-378 may provide robustness to myogenesis through inhibition of Msc 
expression during later stages of the differentiation process. During C2C12 differentiation, miR-378 expres-
sion is increased more than four-fold, with a slight increase on day 1, a larger increase on day 2 and no further 
increase up to day 4, suggesting its key role during early steps of myogenesis11. Interestingly, miR-378 is encoded 
within an intron of the Ppargc1b gene which encodes PGC-1β, a regulator of energy metabolism. As miR-378 
is co-expressed with PGC-1β, it has been suggested to play a role in metabolism and known interactions with 
target genes has confirmed this (reviewed in24). miR-378a-5p has been shown to be down-regulated with age in 
men7. This study also showed that after exercise miR-378a-5p is downregulated in young but not in older people, 
suggesting a blunting effect of age on miR-378 expression in muscle following exercise. miR-378 and several other 
miRNAs also target the components of the insulin-like growth factor-1 (IGF-1) signalling pathway, resulting in 
loss of muscle homeostasis7. However, there have been no studies to date to show that miR-378a-3p, the strand 
investigated in other studies changes with age3.
A recent study identified miR-143–3p as a regulator of the IGF-binding protein-5 (Igfbp5), that regulates IGF 
signalling through binding IGF-1 and IGF-2, in primary myoblasts25. miR-143-3p expression is downregulated in 
satellite cells and muscle progenitors during ageing, and changes in miR-143:Igfbp5 interactions have been pro-
posed to be a part of a compensatory mechanism aimed at improving the efficiency of myogenesis during ageing. 
Interestingly, treatment of myoblasts with the cytokine IL-6, which has been shown to be elevated in circulation 
during ageing26, led to lower expression of miR-143 and an increase in Igfbp525. However, it is not yet clear how 
IL-6 leads to the reduction in miR-143 expression.
We have previously demonstrated the utility of computer simulation models to examine the effect of miRNAs 
in gene regulatory circuits (in submission). These models show how miRNAs affect target gene expression by 
different mechanisms such as positive feedback, negative feedback and positive feedforward loops. Each type of 
mechanism leads to different effects on the target genes and includes pulse-like responses, extended repression, 
delays in responses and fine-tuning. The aim of this study was to use computational modelling to increase our 
understanding of the mechanisms by which individual miRNA:target interactions affect the decline in muscle 
regeneration during ageing. In order to do this, we constructed network models of a subset of miRNAs that are 
known to be important in the maintenance of muscle homeostasis and are up- or down-regulated during ageing. 
To start modelling ageing-associated changes in the muscle, we chose the networks involving miR-1, miR-143, 
miR-181, and miR-378, miRNAs with roles in muscle homeostasis and expression of which is dysregulated in 
muscle and satellite cells during ageing.
Results
The miRNAs miR-1, miR-181, miR-378 and miR-143 affect myogenesis and are down-regulated 
in myogenic progenitors during ageing. In order to create a model of the effects of selected miRNAs on 
myogenesis, we first overexpressed and inhibited these miRNAs in undifferentiated C2C12 cells. Overexpressing 
miR-1, miR-181, or miR-378 improved the efficiency of myogenesis, whereas increased levels of miR-143 
decreased myogenesis efficiency as compared to scrambled-transfected controls (Fig. 1a). Conversely, inhibi-
tion of the miRNAs led to the opposite effect than their overexpression. In addition, all four miRNAs and gene 
expression of MyoD and Myogenin were down-regulated in myogenic progenitor cells during ageing (Fig. 1b,c). 
Experiments were also carried out to validate the model output (Fig. 1d,f), which are described below.
Model 1: miR-1 promotes the switch from quiescence to differentiation. miR-1 expression is 
downregulated in myogenic progenitors during ageing (Fig. 1a,b). We constructed a computational model in 
which we assumed that MyoD upregulates miR-1 expression14 and that miR-1 enhances the degradation of Pax3 
mRNA13. In addition, as Pax3 expression was found to be negatively correlated with MyoD13 we assumed that 
Pax3 inhibits transcription of MyoD resulting in a negative feedback loop (Fig. 2a,b). Experimental data using 
a glioma cell line which does not express miR-1 but expresses high levels of Pax3 showed that transfecting cells 
with miR-1 led to reduced levels of both Pax3 transcript and protein at 48 h13. We validated our model against this 
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data by running simulations for five hours (virtual time) in the total absence of miR-1 and compared this to our 
results in which MyoD induces miR-1 expression. In order to fit our model to this data, it was necessary to assume 
that miR-1 enhances degradation of Pax3 transcript but does not inhibit Pax3 translation. Therefore, we needed 
to include a reaction in which Pax3 mRNA bound by miR-1 could be translated into protein. The model output 
shows that the presence of miR-1 leads to about a 30–50% reduction in Pax3 transcript and protein at 48 h, which 
is in good agreement with the experimental data13 (Supplementary Figure S1).
After validating the model, we simulated the effect of high and low levels of Pax3 on myogenesis over a 10-day 
period. As expected, low levels of Pax3 are associated with high levels of MyoD and miR-1 ensuring that Pax3 
levels remain low and myogenesis can occur (Fig. 2c). Conversely, high Pax3 levels are associated with low levels 
of MyoD and miR-1 enabling Pax3 expression to remain high (Fig. 2d). In addition, we examined the effect of 
miR-1 on the balance between proliferation, quiescence and differentiation. It should be noted that the model also 
includes a reaction in which miR-1 is produced at a very low rate independently of MyoD. If the parameter for 
this reaction is increased, miR-1 expression gradually increases over time, despite the low levels of MyoD, and so 
Pax3 levels decrease, leading to release of the inhibition of MyoD which eventually increases. These interactions 
lead to a further increase in miR-1 levels and further inhibition of Pax3 expression (Fig. 2e). This model suggests 
that a threshold level of miR-1 may play a role in the initial step of myogenesis: a switch from a quiescent to a dif-
ferentiating satellite cell. Our experimental data supported both the role of miR-1 on myogenic differentiation of 
myogenic progenitors from adult and old mice, and the positive regulation of MyoD expression by miR-1 (Fig. 1).
Model 2: a threshold level of miR-181 enhances myogenesis but may also increase muscle atro-
phy or inhibit muscle hypertrophy. The expression of miR-181 is downregulated in myogenic progen-
itors during ageing (Fig. 1a,b). We constructed a model of the miR-181-associated network to demonstrate its 
positive regulation of myogenesis by activating MyoD and inhibiting Sirt-1 expression (Fig. 3a). We assumed that 
Hox-A11 inhibits MyoD expression27 by binding to its promoter to inhibit MyoD transcription, and that miR-181 
inhibits Hox-A11 expression at the protein levels but did not enhance degradation of Hox-A11 mRNA12 (Fig. 3b). 
In addition, we assumed that miR-181 inhibits translation of Sirt-1 and targets Sirt-1 mRNA for degradation 
but does not enhance its degradation rate20. We also included inhibition of FoxO3 by Sirt-123 in the model and 
assumed that FoxO3 upregulates the levels of Mafbx28, which leads to muscle atrophy due to increased protein 
degradation. We carried out simulations of the model with either low or high levels of miR-181 (Fig. 3c,d). Low 
levels of miR-181 lead to high levels of both Hox-A11 and Sirt-1, and low levels of MyoD (Fig. 3c). The converse is 
Figure 1. The role of selected miRNAs in regulating adult myogenesis. (a) MF20 immunostaining showing 
miRNA regulation of myogenic differentiation of primary myoblasts from adult or old mice. Green – MF20, 
blue – DAPI. (b–g) qPCR showing changes in miRNA and gene expression in murine myogenic progenitors 
during ageing or following microRNA overexpression (mimic, miR) or inhibition (antimiR, AM). Expression 
relative to Rnu-6 (miRNA) or β-2 microblobulin (mRNA) is shown, *p < 0.05 as compared to Adult/Adult scr; 
Error bars show SEM; n = 3. Adult – 6 months old, Old – 24 months old, Scr – antimiR scrambled.
www.nature.com/scientificreports/
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true when miR-181 expression is high (Fig. 3d). Previous studies have shown that miR-181 affects protein, but not 
mRNA, levels of Sirt-1 and Hox-A1112,20. Therefore, we validated our model to check whether it agreed with the 
experimental data (Supplementary Figure S2). As in the published data, our model showed that mRNA levels of 
Sirt-1 or Hox-A11 are unaffected by changing the level of miR-181 but protein levels significantly declined when 
miR-181 levels increased. According to our model, as Sirt-1 protein levels decline in the presence of high levels of 
miR-181, FoxO3 is released from the inhibitory effects of Sirt-1 and is able to translocate to the nucleus and tran-
scribe genes such as Mafbx. Mafbx is an E3 ubiquitin ligase that enhances the degradation of muscle-specific pro-
teins leading to muscle atrophy, and so miR-181 may be detrimental in regulating muscle atrophy (Fig. 3c,d). Our 
experimental data supported the role of miR-181 on myogenic differentiation of myogenic progenitors from adult 
and old mice through MyoD (Fig. 1e) and also the role of miR-181 on myotube atrophy/hypertrophy through 
regulating Sirt-1 and Mafbx expression (Fig. 1f).
Model 3: upregulation of miR-378 by MyoD releases the inhibitory effect of Musculin on MyoD 
activity. The expression of miR-378 is downregulated in myogenic progenitors during ageing (Fig. 1). In 
the miR-378-associated model, we assumed that MyoD initiates transcription of miR-37811, that miR-378 tar-
gets Msc mRNA for degradation11, and that Msc binds to the miR-378 gene to prevent MyoD binding29, i.e. 
it inhibits MyoD transcriptional activity (Fig. 4a,b). The model simulation output shows that as miR-378 level 
increases, a simultaneous decrease in Msc levels occurs, therefore the levels of miR-378 and Msc are approxi-
mately anti-correlated (Fig. 4c,d), consistent with experimental data11. We also examined the effect of increasing 
or inhibiting miR-378 levels by varying the parameters which control miR-378 synthesis. Increasing the rate of 
binding of the miR-378 gene by Msc led to lower levels of miR-378, as expected, and led to an increase in Msc 
mRNA levels (Supplementary Figure S3). However, stochastic simulation indicates that there is large variability 
in levels of miR-378 and Msc mRNA with the same parameter value, although the average behaviour is similar to 
the deterministic result (Supplementary Figure S3). Increasing/inhibiting MyoD activity was next simulated by 
varying the rate of binding of MyoD to the miR-378 gene. As MyoD activity increased, miR-378 levels increased, 
as expected, and Msc mRNA levels decreased (the opposite result to varying the rate of binding of Msc to the 
miR-378 gene) as shown (Supplementary Figure S3). Therefore, miR-378 may act in the differentiation process 
Figure 2. A model of miR-1 in muscle. (a) Diagram showing the negative feedback loop. (b) Network diagram 
of full model. (c–e) Model output. (c) Low Pax3 (default parameters). (d) High Pax3 (initially Pax3 = 1000, 
Pax3mRNA = 400, ksynPax3 = 6.0e-5 s−1, ksynPax3mRNA = 0.08 molecules s−1). (e) High Pax3 and increased 
production of miR-1 (parameters as in D except ksynmiR1 = 0.001). Default values for initial amounts and 
parameters are shown in Supplementary Tables S1 and S2 respectively. A larger version of Fig. 2b is shown in 
Supplementary Figure S15.
www.nature.com/scientificreports/
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to maintain MyoD activity. Our experimental data supported the role of miR-378 on myogenic differentiation of 
myogenic progenitors from adult and old mice through regulation of MyoD levels (Fig. 1e).
Model 4: miR-143 is inhibited by prolonged IL-6 signalling resulting in higher levels of myo-
genin. The expression of miR-143 is downregulated in myogenic progenitors during ageing (Fig. 1). We mod-
elled the effects of miR-143 in myogenesis by assuming that miR-143 expression is down-regulated by IL-625 
and that miR-143 inhibits Igfbp5 expression by both enhancing degradation and inhibiting translation of Igfbp5 
mRNA25. Igfbp5 binds to IGF2 and enhances IGF2 binding to the IGF1-R receptor30. This activates Akt sig-
nalling, by increasing phosphorylation of Akt, leading to upregulation of myogenin expression30. We modelled 
IL-6-mediated inhibition of miR-143 by assuming that IL-6 binds to the miR-143 gene to inhibit its transcription. 
This is a simplifying assumption; however the model could be extended when details of the mechanism are better 
known. A simplified diagram and a network of the full model are shown in Fig. 5a,b. We assumed that IL-6 levels 
increase in response to injury and ran simulations by assuming that initially IL-6 levels are high and then decline 
due to negative feedback loops in the IL-6 signalling pathway. In this scenario, miR-143 levels rapidly decline in 
response to IL-6 but by 21 days (as shown experimentally following muscle injury25), miR-143 levels return to 
normal (Fig. 5c). In old tissues, a chronic activation of inflammatory pathways may exist and we modelled this by 
assuming that IL-6 levels show a much slower decline rate after activation, due to dysregulation of feedback loops 
during ageing. In this situation, miR-143 levels decline and remain low even at 21 days following injury (Fig. 5d). 
This agrees well with our experimental data and supports the hypothesis that down-regulation of miR-143 in 
ageing is a compensatory mechanism to help alleviate the decline in muscle regeneration with age25. To examine 
the effect of IL-6 on miR-143 levels, we varied its synthesis rate with both transient and sustained IL-6 signalling 
(Supplementary Figure S4). Due to the inhibitory effect of IL-6 on miR-143 transcription, miR-143 levels only 
increase when IL-6 levels are low, even at higher miR-143 synthesis rates. Therefore, it can only increase when 
IL-6 signalling is transient as shown in Supplementary Figure 4. Our experimental data supported the role of 
miR-143 on myogenic differentiation of myogenic progenitors from adult and old mice through regulation of 
myogenin levels (Fig. 1d).
Model 5: Integrated model. We combined all four models to form an integrated model. As miR-1 and 
miR-143 are MyoD targets, we also added inhibition of miR-1 and miR-143 transcription by Msc. A simpli-
fied diagram of the network is shown in Fig. 6. When we simulated the integrated model with all the default 
Figure 3. A model of miR-181 in muscle. (a) Diagram showing how miR-181 positively regulates myogenesis. 
(b) Network diagram of full model. (c,d) Model output of miR-181 model showing Hox-A11, Sirt-1, Mafbx 
and MyoD protein levels. (c) Low miR-181 (default parameters). (d) High miR-181 (initially miR-181 = 1000, 
ksynmiR181 = 6e-4 s−1). (c,d) Show output from one individual stochastic simulation. Default values for initial 
amounts and parameters are shown in Supplementary Tables S3 and S4 respectively. A larger version of Fig. 3b 
is shown in Supplementary Figure S16.
www.nature.com/scientificreports/
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parameters from the individual models, the simulation output showed that even when Pax3 levels are low, MyoD 
is also low (Supplementary Figure 5). This is due to the high levels of Hox-A11 which inhibits MyoD expression 
(Supplementary Figure 5). If we assume that miR-181 levels are high, Hox-A11 levels decrease resulting in a 
recovery of MyoD levels and this in turn leads to an increase in miR-1 expression (Supplementary Figure 6). 
In addition, miR-378 levels slightly increase, resulting in lower levels of Msc, and miR-143 levels also increase 
after IL-6 levels have declined (compare Supplementary Figures 5 and 6). Since MyoD is also inhibited by Msc, 
we modelled the effect of high levels of miR-378 when miR-181 is low (Supplementary Figure 7). With lower 
levels of Msc, MyoD levels increase (as can be seen by the resulting higher levels of miR-1) but the effect is mod-
est as Hox-A11 levels are high. If miR-181 and miR-378 levels are both high, then there is no significant effect 
on MyoD levels but miR-1 is further increased due to less inhibition of MyoD activity by Msc (Supplementary 
Figure 8). We then simulated the model under conditions of high Pax3 with miR-181 and miR-378 set at low 
levels (Supplementary Figure 9) and as expected MyoD levels are very low. Increasing both miR-181 and miR-378 
under these conditions led to a modest recovery in MyoD levels and increased activity (as seen by an increase 
in miR-1 and miR-378) and at late timepoints miR-143 starts to increase (Supplementary Figure 10). Increasing 
miR-1 levels and its synthesis rate at the start of the simulation results in a faster decline in Pax3, and MyoD levels 
start to recover earlier although they do not seem to reach higher levels (Supplementary Figure 11).
We varied the transcription rate of miR-143 with both transient and sustained IL-6 signalling and the effect 
was similar to that obtained in the individual model, except that a higher rate of miR-143 transcription is needed 
due to the additional inhibition of MyoD in the integrated model by both Hox-A11 and Msc (Supplementary 
Figure 12). However, increasing both miR-181 and miR-378 resulted in higher miR-143 levels and the results of 
varying ksynmiR143 in the integrated model is then very similar to the individual model (Supplementary Figure 13). 
Finally, we varied the rate of miR-378 transcription and the model output showed that decreasing miR-378 tran-
scription resulted in higher levels of Msc protein (with a slight increase in mRNA) but no effect on MyoD levels 
(Supplementary Figure 14). There was also lower levels of miR-1 but no effect on miR-143 or miR-181 levels 
(Supplementary Figure 14). Conversely increasing miR-378 transcription led to lower levels of Msc protein, no 
effect on MyoD levels and higher levels of miR-1. In addition, miR-143 levels showed a slight recovery after 9 days 
but miR-181 levels were still unaffected (Supplementary Figure 14).
Figure 4. A model of miR-378 in muscle. (a) Diagram showing positive auto-regulation of MyoD activity. 
(b) Network diagram of full model. (c,d) Model output showing inverse relationship between MyoD activity 
(indicated by levels of miR-378) and Msc levels. (c) One individual simulation. (d) Mean (bold curves) and 
standard deviation (shaded area) from 100 simulations. Default values for initial amounts and parameters are 
shown in Supplementary Tables S5 and S6 respectively. A larger version of Fig. 4b is shown in Supplementary 
Figure S17.
www.nature.com/scientificreports/
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Discussion
We have developed a set of models to illustrate how computational modelling can be used as an additional tool 
for investigating the behaviour of miRNA:target interactions in muscle homeostasis, specifically in adult myo-
genesis. To build a model that starts to decipher ageing-associated changes in muscle regeneration, we selected 
four different miRNAs known to be important in muscle homeostasis in adulthood and/or ageing and first built 
individual models of each one, based on current experimental data relevant to muscle regeneration. At this stage, 
we kept the models as simple as possible but as they have been developed using the Systems Biology Markup 
Language (SBML) modelling standard31, they are very amenable to modification and can be extended to included 
more interactions as required, for example as new data emerge from experimental studies. Other computational 
approaches have recently been developed which may provide further information for the models. In particular, 
Figure 5. A model of miR-143 in muscle. (a) Diagram showing key components and interactions. (b) Network 
of full model. (c,d) Model output. (c) Transient IL-6 response (default parameters). (d) Slower decline of IL-6 
leads to prolonged signalling (kdegIL6 = 1e-6 s−1). Default values for initial amounts and parameters are shown in 
Supplementary Tables S7 and S8 respectively. A larger version of Fig. 5b is shown in Supplementary Figure S18.
Figure 6. Simplified network diagram of integrated model. Key: blue boxes: miRNAs, green boxes: proteins 
that activate myogenesis; red boxes: outputs representing atrophy; mustard boxes: other regulatory proteins.
www.nature.com/scientificreports/
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methods for predicting miRNAs associated with disease using miRNA-disease heterogeneous networks have 
been developed, e.g.32,33, and are the focus of three recent reviews34–36.
Computational modelling has previously been extensively used in the field of cancer (reviewed in37), and also 
established as a tool in modelling congenital heart disease (reviewed in38). Despite the success of modelling in 
these fields, there is still a paucity of computational models in the study of human diseases. In particular, to our 
knowledge, there is currently a lack of computational models of the underlying molecular mechanisms leading to 
muscle dysfunction in ageing and disease. Our method has the potential to be used to help increase our under-
standing of other diseases related to muscle such as Duchenne Muscular Dystrophy (DMD) and myositis. DMD 
is a severe type of muscular dystrophy for which there is currently no cure. It is caused by a mutation in the dys-
trophin gene, leading to dysregulation in calcium and other signalling pathways, mitochondrial dysfunction and 
necrosis of muscle fibres. However, the underlying pathways are complex and not fully understood, suggesting 
the need for computational modelling. Considering the limited success of current therapies undergoing clinical 
trials, additional computational approaches could possibly be used to enhance the success of exon skipping or 
to propose other therapies. Myositis is charactersied by the infiltration of immune cells into the muscle leading 
to chronic inflammation, however, the mechanisms by which damage to muscle occurs is poorly understood. 
Particularly, the mechanism by which changes in the immune cells infiltrating the muscle and changes within 
the muscle tissue itself contribute to the onset of myositis are not understood. We suggest that computational 
modelling could be useful in simulating the effects of an increase in pro-inflammatory cytokines on the function 
of muscle cells.
The miR-1 model illustrates how MyoD initiates a positive feedback mechanism to ensure that its expression 
is switched on and remains on during mygonesis. mir-1 is central to this switch as it is upregulated by MyoD and 
then targets Pax3, an inhibitor of MyoD. This model could be extended in various ways. First, it would be inter-
esting to include dimerisation of MyoD, since this is required for its transcriptional activity. This would affect the 
concentration of MyoD required for its activity and would help to prevent inappropiate upregulation of genes 
when MyoD is at low concentrations. It has also been shown that miR-1 targets Hdac439, a histone deacetylase 
which represses Mef2C, an essential myogenic transcription factor. This would provide an additional pathway 
by which miR-1 promotes myogenesis. Furthermore, a study has shown that miR-1 targets Hsp70 to antagonise 
the inhibitory effect of Hsp70 on Akt phosphorylation40. Phosphorylated Akt, inactivates Foxo3 which in turn 
inhibits two E3 ubiquitin ligases, Murf1 and Atrogin-1, both of which are implicated in muscle atrophy due to 
increased protein degradation28.
The miR-181 model suggests that above a threshold level, miR-181 promotes myogenesis, however it may also 
lead to either muscle atrophy or inhibition of hypertrophy. This is due to the inclusion of two targets: Hox-A11 
and Sirt-1, which both inhibit myogenesis via different pathways. In addition, Sirt-1 inhibits muscle atrophy and 
promotes hypertrophy. Therefore, the effect of miR-181 via Sirt-1 is complex and requires further investigation 
into what determines the different outcomes due to Sirt-1. External conditions such as mechanical signals and 
nutrient supply regulate Sirt-1 activity and so the effect of Sirt-1 may depend on the energy status of the cell. 
(reviewed in41). Sirt-1 activity is also dysregulated in ageing leading to lower expression of antioxidants and 
increased oxidative stress42. Moreover, Sirt-1 has been shown to positively regulate metabolic state of satellite cells 
and autophagy, which is also associated with FoxO3 activity43. Therefore, including more detail of the pathways 
involving Sirt-1 would be important in the context of modelling age-related changes in muscle regeneration.
Similarly to miR-1, we modelled the role of miR-378 in MyoD positive auto-regulation. Since many miRNAs 
are thought to have fine-tuning effects on gene expression, it is not surprising that there are several miRNAs 
working in similar pathways. Whereas miR-1 inhibits Pax3 expression which down-regulates MyoD, miR-378 
inhibits Musculin, a transcription factor that binds to the same target genes as MyoD, thereby inhibiting MyoD 
activity. Therefore, increased expression of both miR-1 and miR-378 would result in increased expression and 
higher activity of MyoD. Our model of miR-378 is currently simple but could be expanded to include its role 
in metabolism. The gene for miR-378 is in the first intron of Pgc-1β and so is expressed more in metabolically 
active tissue and it has been shown to activate the pyruvate-PEP futile cycle in skeletal muscle of mice whereby 
it enhances lipolysis in adipose tissue and ameliorates obesity44. A further study by the same group showed that 
miR-378 targets Igfr1 in mice leading to defective muscle regeneration45.
In the first three models, the miRNAs had mainly postive effects on muscle regeneration, whereas miR-143 
has been shown to have detrimental effects as it targets components of the insulin signalling pathway leading to 
inhibition of myogenesis. Interestingly, miR-143 is downregulated in ageing which may be due to chronic inflam-
mation. Our model was able to simulate the effects on miR-143 inhibition on myogenesis and showed that low 
miR-143 levels led to higher levels of Igfbp5 and an increase in myogenin (the model readout for myogenesis) in 
agreement with our experimental data (Fig. 1d) and a previous study25. The same study showed that miR-143:Ig-
fbp5 interactions regulate myoblast senescence. The model could be developed further to study this by adding 
components of the senescent pathway such as p16 and Rb. Finally adding in further detail of the IL-6 pathway 
may help to unravel its complex signalling pathways in muscle since it has been shown to have mainly beneficial 
but also detrimental effects46.
We illustrated the approach with miR-1, miR-181, miR-378 and miR-143 but intend to develop further models 
of other miRNAs. For example, miR-23a and miR-182 regulate expression of atrophy genes47,48, miR-128 down-
regulates genes involved in the insulin/IGF1 signalling pathway in skeletal muscle49, and miR-206, a miRNA in 
the same family as miR-1 also targets Pax313. For a comprehensive discussion of the role of miRNAs in skeletal 
muscle we refer the reader to recent reviews10,50. Since miRNAs are involved in many different gene regulatory 
circuits and affect multiple signalling pathways, it will be important to investigate the cross-talk between miR-
NAs, their regulators and their targets. Computational modelling can contribute to this by combining models of 
individual miRNAs into an integrated model and then simulate the effect of perturbing one or more components 
on the overall behaviour of the system. We illustrated this approach by combining each of the models described 
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in this paper into an integrated model. The output from this model showed that crosstalk between the pathways 
affected levels of miRNAs themselves, especially those that are regulated by MyoD, due to different pathways 
having an inhibitory effect on MyoD activity. In addition, we examined the effects of overexpressing each miRNA 
individually and also in combination and showed that miR-1, miR-181 and miR-378 all have positive effects on 
myogenesis, whereas overexpression of miR-143 leads to detrimental effects due to lower levels of myogenin. This 
is consistent with our experimental data (Fig. 1). It has been suggested that down-regulation of miR-143 with 
age may be a compensatory effect and our model supported this idea with miR-143 levels declining in response 
to persistent IL-6 signalling. It would be interesting to extend our model to include other mechanims of ageing 
such as oxidative damage, redox regulation of miRNA genes and dysregulation of transcriptional regulation and 
to simulate the model over longer timescales to represent an ageing organism. It would also be important to study 
the effects of ageing on muscle in relation to physical activity, since a decline in activity is common in ageing and 
exarcerbates the loss of muscle mass and function51.
Although we have modelled complex processes, such as ageing during which multiple mechanistic and com-
pensatory changes within tissues and surrounding environemnt occur, we kept the models as simple as possible 
but included enough detail so that they are supported by the experimental data in a meaningful way. It is possible 
to improve the fit of the models to the data by making them more complex. This, however, may then have the 
disadvantage of not being useful for interpreting the underlying dynamics of the system (a problem commonly 
caused by over-fitting) or for making predictions. It should be pointed out that we do not claim that we have 
developed the “best models” as modelling is a dynamic process and future research may produce new data which 
is inconsistent with our models. In this case the model output may provide clues as to what is missing or incorrect 
in the models so that modifications can be made. SBML models are very amenable to this process and examples 
of adapting models for new data has been illustrated in the literature.
Finally, there are major advantages of using computational modelling from both financial and ethical per-
spectives. For example, computer simulation can be used to investigate the effects of single and multiple targets 
before in vivo studies, so that only targets that have been predicted by the model to be beneficial need to tested. 
The models can also take into account redundancy as has been observed for miR-1 and miR-206 in which single 
knock-outs in mice have hardly any phenotype13,52, highlighting the possible need for a multiple target approach. 
Finding the best combination of multiple targets may be infeasible and unethical in an experimental setting but 
well-suited to a computational approach.
Methods
Model construction. All models were constructed using SBML shorthand53 and a Python tool to convert 
the code into SBML31. Simulations were performed in COPASI 4.1854 using either the deterministic LSODA 
algorithm55 or the stochastic direct method which is based on the Gillespie algorithm56. The LSODA algorithm 
solves stiff and non-stiff systems of ordinary differential equations by automatic selection55. We used the COPASI 
default parameters for this solver (relative tolerance = 1e-6; absolute tolerance = 1e-13; maximum internal step 
size = 10000). The stochastic Gillespie direct method simulates every reaction, updating the number of molecules 
of each species after a reaction occurs. At each time-step a random number is generated to determine the next 
reaction to occur and the time interval to that reaction. The probability of any particular reaction occurring is 
proportional to its associated parameter value multiplied by the number of substrate molecules. Each stochastic 
simulation produces a different trajectory. Therefore multiple stochastic simulations were also carried out on a 
cluster using software developed at Newcastle University57 which also used the Gillespie algorithm. This software 
is encoded in the C programming language and is available on request. Simulation data were analysed and plotted 
in R using ggplot258. Network diagrams of the models were created in CellDesigner59 which used the Systems 
Biology Graphical Notation60.
Isolation of primary myoblasts from mouse skeletal muscle. Primary myoblasts from adult (6 
months old) and old (24 months old) mice were prepared from EDL muscles via collagenase and dispase diges-
tion as described by us previously61. This allowed for isolation of a pure population of primary myoblasts retain-
ing the expression patterns of selected miRNAs.
Cell culture. Mouse primary myoblasts were maintained in DMEM media supplemented with 20% fetal 
bovine serum, 10% horse serum and 1% penicillin/streptomycin. To induce myogenic differentiation 90% con-
fluent cells were cultured in DMEM supplemented with 5% horse serum and 1% penicillin/streptomycin (DM). 
Myoblast differentiation was assessed 10 days following the switch to DM by immunostaining for myosin heavy 
chain using the MF20 antibody52. Images were taken using Zeiss fluorescent microscope and analysed using 
ImageJ as in25.
transfections. Myoblasts were transfected with 100 nM miRNA mimic or antimiR (Qiagen) or scrambled 
antagomiR not predicted to bind to any know miRNA13, as indicated in figures, using Lipofectamine 2000TM 52. 
AntimiR-scrambled-transfected cell served as controls. This provided a transfection efficiency of 40–70%, 
depending on the molecule transfected as described previously52.
Real-time PCR. RNA isolation and quantitative real time PCR were performed using standard methods as 
described previously62. cDNA synthesis (mRNA) was performed using 500ng RNA and SuperScript II accord-
ing to the manufacturer’s protocol (Invitrogen). cDNA synthesis (miRNA) was performed using 100ng RNA 
and miRscript RT kit II according to the manufacturer’s protocol (Qiagen). qPCR analysis was performed using 
miRScript SybrGreen Mastermix or sso-Advanced SybrGreen Mastermix in a 20 µl reaction (Qiagen or Biorad, 
respectively). Expression relative to β-2 microblobulin and/or 18S (mRNA) or Rnu-6 and/or Snord-61 (miRNA) 
was calculated using delta delta Ct method.
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Mice. The study was performed using male wild type C57Bl/6 mice (adult: 6 months old; old – 24 months 
old). Mice were obtained from Charles River (Margate). All mice were maintained under specific-pathogen free 
conditions and fed ad libitum a standard chow and maintained under barrier on a 12-h light-dark cycle. For tis-
sue collection, mice were culled by cervical dislocation. The tissues were immediately excised, frozen and stored 
at −80 °C. Experiments were performed in accordance with UK Home Office guidelines under the UK Animals 
(Scientific Procedures) Act 1986 and received ethical approval from the University of Liverpool Animal Welfare 
and Ethical Review Body (AWERB). Primary myoblasts from adult (7 months old) and old (24 months old) mice 
were prepared from EDL muscles following single fibre isolation as previously described63,64. These myoblasts 
retained the expression patterns of miRNAs.
Data Availability. The SBML code for each of the four individual models and the integrated model was depos-
ited in the public repository, Biomodels65 and assigned the identifiers MODEL1704110000-MODEL1704110004.
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